NCT07495813
A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: The development of RO7763505 for coronary artery disease has been discontinued.
- Eligibility criteria expanded, about 12 words
- Final enrollment: 39 participants (planned 196)
- Primary completion date changed from estimate of Oct 30, 2026 to Aug 20, 2026
- Notable Primary and study completion moved earlier from Feb 15, 2028 to Oct 30, 2026
- Enrollment closed, study ongoing
- Site details revised
- Study Status, Contacts/Locations, Referencesv4
- Minor Primary completion pushed from Dec 31, 2027 to Feb 15, 2028v3
- Minor Study completion pushed from Dec 31, 2027 to Feb 15, 2028v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part 1a and Part 1b: Percentage of Participants With Adverse Events (AEs)
Timeframe: Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks
Part 1c: Plasma Concentration of RO7763505 in Fasted and fed State
Timeframe: Approximately up to 3 Weeks
Part 2: Percentage of Participants With AEs
Timeframe: Approximately up to 6 Weeks
Secondary (5)
Part 1a and Part 1b: Plasma Concentration of RO7763505 and its Metabolites
Part 1a and Part 1b: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated Interleukin-1 Beta ( IL-1β)
Part 1c: Percentage of Participants With AEs
Part 2: Plasma Concentration of RO7763505 and its Metabolites
Part 2: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated IL-1β
Arms and interventions
Part 1: SAD, MAD, and Food Effect in Healthy ParticipantsExperimental
Healthy participants will receive RO7763505 or matching placebo.
Part 2: In Stable CAD ParticipantsExperimental
Participants with stable CAD will receive RO7763505 or matching placebo.
Drugs: RO7763505, Placebo
Sites
1 site in 1 country
- ICON Plc (LPRA) - NetherlandsGroningen, Netherlands